Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
about
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesPrecision medicine in breast cancer: reality or utopia?Targeted therapies in breast cancer: New challenges to fight against resistance.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Modern therapies and iatrogenic changes in breast pathology.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.Medicine: Eyes on the target.Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer.The Cytotoxic and Antimigratory Activity of Brazilin-Doxorubicin on MCF-7/HER2 CellsNeoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this FieldClinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
P2860
Q28072897-20920F09-719E-4F00-B7AB-15BF393817C3Q33809114-3A266BEE-70D2-421E-8558-933CC69ACDD3Q37743048-8FBE3119-4B6A-43EC-8A07-15BBE24EAF63Q38812867-FBE8B974-174D-4A86-B073-A8F80B526B6FQ39037636-6478FF1D-B598-4476-BF40-E92D875BA4FBQ39421814-7A752D39-ABA7-448E-9992-E2FE6F7EA155Q41708988-F0C64990-C2A1-4AF0-9C02-5F39F83028CBQ48202060-F8F0FA83-1F23-457B-BD6A-90BFEF6343EBQ51016839-3D7B5859-D7DE-4288-BC58-E0ABE6C49081Q52578959-394F25FC-9A4D-4DBF-B25F-07B81AA99EC7Q53691004-DB3A67EE-D35E-40D9-8484-74FA3464274EQ55036430-38106BEA-8C8E-4F33-91AD-02EA3B9AD3AAQ55309854-B6CD2538-7013-4046-ABDD-DA1412149264Q57136097-3A33C4CD-7FD8-4580-9331-84367F6D92ECQ57495764-E0148D98-D0FE-42E7-AA67-8726AAF9AE84Q58764956-33344455-897F-4AE4-9C0A-E002ADCD0F91
P2860
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Upregulation of ER Signaling a ...... reated with Anti-HER2 Therapy.
@ast
Upregulation of ER Signaling a ...... reated with Anti-HER2 Therapy.
@en
type
label
Upregulation of ER Signaling a ...... reated with Anti-HER2 Therapy.
@ast
Upregulation of ER Signaling a ...... reated with Anti-HER2 Therapy.
@en
prefLabel
Upregulation of ER Signaling a ...... reated with Anti-HER2 Therapy.
@ast
Upregulation of ER Signaling a ...... reated with Anti-HER2 Therapy.
@en
P2093
P2860
P1476
Upregulation of ER Signaling a ...... Treated with Anti-HER2 Therapy
@en
P2093
Agostina Nardone
Alejandro Contreras
Anne C Pavlick
C Kent Osborne
Carmine De Angelis
Carolina Gutierrez
Gary C Chamness
Huizhong Hu
Jenny C Chang
Joe W Gray
P2860
P304
P356
10.1158/1078-0432.CCR-14-2728
P407
P577
2015-05-26T00:00:00Z